The Impact of Information Systems on Management Performance in the Pharmaceutical Industry

2015 ◽  
Vol 17 (3) ◽  
pp. 56-73 ◽  
Author(s):  
Sherif Elshorbagy ◽  
Lalit Garg ◽  
Vipul Gupta ◽  
Gopalakrishnan Narayanamurthy ◽  
Yosuf Abd Al Oraini
Keyword(s):  
Pharmaceutical Industry ◽  
Pharmaceutical Companies ◽  
Successful Implementation ◽  
Strategic Decisions ◽  
Management Performance ◽  
Business Operations ◽  
Lack Of Information ◽  
Short Time ◽  
And Control ◽  
The Impact

There are many aspects that should be considered while implementing ISs in pharmaceutical companies. This is due to the various regulations and standards that the governmental authorities impose on these companies. In addition, any audit from US Food and Drug Administration (FDA) or other authorities will require computer system validation to be performed for the implemented ISs to ensure that all areas that affect the drugs lifecycle are following the required standards, and that each single process in this lifecycle is validated. Unfortunately, many pharmaceutical companies didn't recognize yet the importance of ISs to their businesses. The research presented in this paper examines the value of using an information system (IS) in pharmaceutical environment and how it can be a key component of improving the operational and process effectiveness by supporting the strategic decisions and enabling the decision-makers to take their decisions in short time. Lack of information in pharmaceutical companies is one of the reasons why these companies will not be able to compete in this competitive market because the delays in taking decisions, product lifecycle, and supply chain. Pharmaceutical companies required to follow various regulations and standards, and ISs are the tools that can be mapped to these standards and control the business operations without any obstacles. The authors conducted a comprehensive study to investigate the role of ISs in the pharmaceutical industry through a review of existing literatures relevant to the research subject and through a questionnaire survey with 54 participants working in the pharmaceutical industry in different countries in the Middle East. The survey aimed to understand the present status of ISs in pharmaceutical companies and the impact of ISs on management performance, operation improvement, end-users productivity, and compliance with the regulations and standards of the pharmaceutical industry in their companies. Moreover, the survey also aimed to identify the catalysts behind successful implementation of ISs.

scholarly journals TRANSFORMATIONAL TRENDS AND INNOVATIVE FACTORS IN THE DEVELOPMENT OF THE WHOLESALE AND RETAIL SECTORS OF THE PHARMACEUTICAL MARKET

2021 ◽  
pp. 27-35
Author(s):  
E. A. Bykova
Keyword(s):  
Pharmaceutical Industry ◽  
Structural Changes ◽  
State Regulation ◽  
Pharmaceutical Market ◽  
Essential Medicines ◽  
Pharmaceutical Companies ◽  
Innovative Development ◽  
Market Participants ◽  
The Impact

The article discusses important features of trends in the transformation of the wholesale and retail level of the Russian medicinal market in the context of innovative factors in the development of the pharmaceutical industry in Russia. The paper gives a general assessment of the impact of state regulation of the maximum selling prices for medicines from the list of vital and essential medicines on the profitability of the market. The author presents a simplified institutional scheme of interaction between distributors and other market participants. The study discusses important aspects and tactical steps of the distribution and pharmacy level of the Russian pharmaceutical market. The article gives the ratings of the leading distribution pharmaceutical companies in Russia and analyses the peculiarities of their structural changes under the influence of innovative development factors. The paper gives ratings of leading pharmacy chains and analyses the features of new structural formations – associations. The author proposes the term of “polarization” for wholesale and retail companies.

scholarly journals Open innovation: An opportunity for Pharmerging countries to close the technology gap?

2014 ◽  
Vol 5 (1) ◽  
pp. 19
Author(s):  
Hind Louiza Chitour
Keyword(s):  
Pharmaceutical Industry ◽  
Open Innovation ◽  
Health Expenditures ◽  
Pharmaceutical Companies ◽  
Closed Model ◽  
Health Market ◽  
Intangible Benefits ◽  
Critical Phase ◽  
Innovation Model ◽  
The Impact

The pharmaceutical industry is entering a critical phase in its history, with decliningprofits and patent cliffs fallouts awaiting their former blockbuster drugs. Several hypotheseshave been formulated to explain the causes of this downfall whether it is the drought in theirR&D pipelines, the rising competition of generics or the ever-increasingpressure from healthcareproviders such as governments seeking to curb their health expenditures thus causing priceerosion. However, rather than striving to find the root causes of the issues the industry isfacing, the major players in the Pharma field should focus on implementing measures totransform the very structure of the pharmaceutical companies and change the drug discoveryand commercialization processes. These core changes that the pharmaceutical sector has toundergo could be achieved through several methods. One of the most suggested solutions tothis R&D bottleneck could be shifting from the traditional “closed model” towards a new “openinnovation” model based on collaboration of Pharma companies whether it includes workingtogether with a biotech company, CROs, Academia or local Pharma manufacturer. This openinnovation model is believed to foster innovation and invigorate the agonizing R&D Pharmasector as it proved itself to be effective resulting in innovative projects and ideas in the ITsector. It is in this context that this paper will address the opportunity emerging pharmaceuticalmarkets could benefit from when this open innovation model is applied to the pharmaceuticalindustry. Mainly, we will discuss the integration of this strategy within big Pharma companiesin their efforts to enter what is designated as “Pharmerging countries” in general with a specialfocus on one key global health market: China. We will discuss the impact of this innovationstrategy could bring in terms of both tangible and intangible benefits and potential drawbacks.

Discussion on Strengthening Financial Supervision of Pharmaceutical Industry under the Background of New Medical Reform

2017 ◽  
Vol 23 (3) ◽  
Author(s):  
Chunjiang Yang ◽  
Xiuli Tan ◽  
Yujiang Yang ◽  
Anqel Chen
Keyword(s):  
Pharmaceutical Industry ◽  
Financial Regulation ◽  
Market Competition ◽  
Living Environment ◽  
Financial Supervision ◽  
Pharmaceutical Companies ◽  
Existing Problems ◽  
Medical Reform ◽  
And Control ◽  
Pharmaceutical Enterprises

Abstract: with the continuous development of the economy and the improvement of the medical technological level, China's pharmaceutical industry is also undergoing sustainable development while the market competition among pharmaceutical companies is being intensified. Leading the operation of pharmaceutical companies and promoting the progress of the pharmaceutical industry, financial regulation is the most important part of many management projects. Hence, strengthening the financial supervision of pharmaceutical companies has become the key to the development of the pharmaceutical industry. However, the financial supervision of domestic pharmaceutical companies under the new medical reform shows many problems, such as poor concept of financial supervision, weak basic supervision, weak budget management and control as well as poor cost control capacity, which make the financial supervision of pharmaceutical enterprises can not proceed smoothly. Therefore, corresponding countermeasures need to be developed. By analyzing the changes of the living environment of domestic pharmaceutical enterprises and the development of financial supervision under the new medical reform, this paper discusses the existing problems in the financial supervision of pharmaceutical enterprises, and puts forward corresponding measures to promote the development of the pharmaceutical industry.

TOPSIS approach to prioritize critical success factors of TQM

2016 ◽  
Vol 28 (2) ◽  
pp. 235-249 ◽  
Author(s):  
Gholamhossein Mehralian ◽  
Jamal A Nazari ◽  
Hamid Reza Rasekh ◽  
Sajjad Hosseini
Keyword(s):  
Pharmaceutical Industry ◽  
Emerging Markets ◽  
Critical Success Factors ◽  
Success Factors ◽  
Successful Implementation ◽  
Pharmaceutical Sector ◽  
Content Type ◽  
Critical Success ◽  
Topsis Approach ◽  
The Impact

Purpose – The pharmaceutical industry has a critical impact on health promotion. It is essential to identify and prioritize the critical success factors (CSFs) within this industry to ensure successful implementation of total quality management (TQM). Therefore, the purpose of this paper is to identify and prioritize CSFs that affect TQM successful implementation in the pharmaceutical industry. Design/methodology/approach – Based on a thorough review of the literature and building on the earlier studies, a valid questionnaire was developed and sent to 320 managers in pharmaceutical sector. In total, 210 completed questionnaires were returned. The technique for order of preference by similarity to ideal solution (TOPSIS) was used to rank and prioritize CSFs. Findings – Results of the data analyses showed that information and analysis, management commitment, relationship with suppliers, and customer focus are the top four CSFs for the successful implementation of TQM in the pharmaceutical sector. Originality/value – Using TOPSIS approach, this is the first study that determines CSFs that have impact on successful implementation of TQM in the pharmaceutical sector. There have been limited studies investigating the CSFs in developing countries. The findings will be useful in helping manager to successfully implement TQM in emerging markets. The approach will help future studies to examine the impact of successful implementation of TQM on firm performance in other industries and in emerging markets.

scholarly journals The Effects of Three Chlorhexidine-Based Mouthwashes on Human Osteoblast-Like SaOS-2 Cells. An In Vitro Study

2021 ◽  
Vol 22 (18) ◽  
pp. 9986
Author(s):  
Giulia Brunello ◽  
Kathrin Becker ◽  
Luisa Scotti ◽  
Dieter Drescher ◽  
Jürgen Becker ◽  
...  
Keyword(s):  
Cell Viability ◽  
Cetylpyridinium Chloride ◽  
Control Cell ◽  
In Vitro Study ◽  
Control Group ◽  
Sterile Saline ◽  
Lack Of Information ◽  
And Control ◽  
The Impact

Several decontamination methods for removing biofilm from implant surfaces during surgical peri-implantitis treatment have been reported, including the intraoperative usage of chlorhexidine (CHX)-based antiseptics. There is a lack of information on possible adverse effects on bone healing. The study aimed to examine the impact of three CHX-based mouthwashes on osteoblast-like cells (SaOS-2) in vitro. Cells were cultured for three days in 96-well binding plates. Each well was randomly treated for either 30, 60 or 120 s with 0.05% CHX combined with 0.05% cetylpyridinium chloride (CPC), 0.1% CHX, 0.2% CHX or sterile saline (NaCl) as control. Cell viability, cytotoxicity and apoptosis were assessed at day 0, 3 and 6. Cell viability resulted in being higher in the control group at all time points. At day 0, the CHX 0.2 group showed significantly higher cytotoxicity values compared to CHX 0.1 (30 s), CHX + CPC (30 s, 60 s and 120 s) and control (60 s and 120 s), while no significant differences were identified between CHX + CPC and both CHX 0.1 and NaCl groups. All test mouthwashes were found to induce apoptosis to a lower extent compared to control. Results indicate that 0.2% CHX presented the highest cytotoxic effect. Therefore, its intraoperative use should be carefully considered.

scholarly journals CURRENT TRENDS IN INTERNATIONAL MERGERS AND ACQUISITIONS OF PHARMACEUTICAL COMPANIES

2021 ◽  
Vol 7 (2) ◽  
pp. 97-108
Author(s):  
Yana S. Sinitsova
Keyword(s):  
Pharmaceutical Industry ◽  
Mergers And Acquisitions ◽  
Statistical Data ◽  
Comprehensive Approach ◽  
Pharmaceutical Companies ◽  
High Significance ◽  
Geographical Structure ◽  
Current Trends ◽  
International Mergers ◽  
The Impact

The article analyzes the results of mergers and acquisitions of global pharmaceutical companies and  their  impact  on  the  global  pharmaceutical  industry.  The  relevance  of  this  research is determined by the high significance of mergers and acquisitions of global pharmaceutical companies on the global pharmaceutical industry and market. A comprehensive approach is used to assess the impact of mergers and acquisitions of pharmaceutical companies on the global pharmaceutical  industry.  The  article  presents  statistical  data  on  the  volume  and  number  of venture  investments  in  the  pharmaceutical  and  biotechnological  industries.  The  reasons  for mergers and acquisitions by pharmaceutical companies, as well as the dynamics of the activity of such transactions, are determined. The geographical structure of stock transactions and the total number of mergers and acquisitions of pharmaceutical companies are presented, as well as examples of the largest mergers and acquisitions of pharmaceutical companies.

scholarly journals Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study

BMJ Open ◽  
2019 ◽  
Vol 9 (2) ◽  
pp. e024928 ◽  
Author(s):  
Lisa Parker ◽  
Emily A Karanges ◽  
Lisa Bero
Keyword(s):  
Pharmaceutical Industry ◽  
Codes Of Conduct ◽  
Code Of Conduct ◽  
Regulatory System ◽  
Healthcare Sector ◽  
Pharmaceutical Companies ◽  
Reporting Requirements ◽  
Regulatory Systems ◽  
The Impact ◽  
Observational Database Study

ObjectivesTo describe and quantify disclosed payments from the pharmaceutical industry to the healthcare sector, and to examine the impact of the 2015 changes to Australia’s self-regulated system of transparency.DesignObservational database study.SettingAustralia.ParticipantsPublicly available reports submitted by members of Australian pharmaceutical industry trade organisations, Medicines Australia and the Generic and Biosimilar Medicines Association (GBMA) (October 2011–December 2017).ExposureChanges to transparency reporting requirements with the updates of pharmaceutical industry Codes of Conduct in 2015.Main outcome measuresElements of healthcare sector spending that members of industry organisations are required to publicly disclose; cumulative amount of disclosed spending (monthly average) in the year prior to and following the revision.ResultsThere was a 34.1% reduction in disclosed spending from Medicines Australia member companies in the year after the 2015 changes to the Code of Conduct were introduced ($A89 658 566 in the preceding year, October 2014–September 2015; $A59 052 551 in the following year). The new Code allowed for reduced reporting of spending on food and beverages at events and for sponsored healthcare professionals. However, there was enhanced transparency around identification of individual health professionals receiving payments. GBMA member reporting totalled $A2 580 402 in the year prior to the revision, then ceased.ConclusionsThis study shows the limitations of a self-regulatory system around industry disclosure of spending. We advocate for robust regulatory systems, such as legislation, to promote mandatory long-lasting public transparency.

scholarly journals Assessment of strategic decisions of enterprises operating in the international marketing in the era of new technologies

2020 ◽  
Vol 30 (3) ◽  
Author(s):  
Małgorzata Łęgowik-Małolepsza
Keyword(s):  
Competitive Advantage ◽  
Return On Investment ◽  
New Technologies ◽  
Leverage Effect ◽  
Strategic Decisions ◽  
Chemical Company ◽  
Business Operations ◽  
Research Gap ◽  
The Impact

In the paper, the issue of assessment of strategic decisions in the company is approached, while indicating their impact on the implementation of modern technological solutions and the methods for their financing. The study is divided into two basic parts, namely theoretical and empirical. In the theoretical part, the essence of the strategy of the company is depicted, taking into account the impact of strategic decisions on the changes in the adopted strategy of the enterprise based on the literature studies. The considerations presented in the empirical part include the results of the research conducted in the multinational chemical company. The objective of the study is to learn and assess the relationships between the implementation of modern technological solutions and the effectiveness of strategic decisions on the methods for their financing. The research methods applied to accomplish the objective are literature studies, a case study and the following techniques related to analysis are used: the analysis of return on investment, and the analysis of financial leverage effect. The issue of assessment of strategic decisions is important and up-to-date due to its impact on the continuity of business operations and maintaining a competitive advantage on the market. This study is an attempt to fill the observed research gap regarding the relationships between the implementation of modern technological solutions and the effectiveness of strategic decisions on the methods for their financing.

The Interplay of Strategic Management and Information Technology

2011 ◽  
pp. 29-41
Author(s):  
Zaiyong Tang ◽  
Bruce Walters
Keyword(s):  
Information Technology ◽  
Strategic Management ◽  
Organizational Performance ◽  
Information Provision ◽  
Monitoring And Control ◽  
Strategic Decisions ◽  
Strategic Emphasis ◽  
Historical Developments ◽  
And Control ◽  
The Impact

The authors trace historical developments in the fields of information technology (IT) and strategic management. IT’s evolution from the mainframe era to the Internet era has been accompanied by a shift in the strategic emphasis of IT. In the early days, IT’s contribution to the organization was largely information provision, monitoring and control. Current research at the intersection of IT and strategic management increasingly highlights the impact of IT in terms of informing strategic decisions and enabling information flow vis-à-vis all manner of organizational processes. We believe these fields are ripe for research focusing on their complementary impact on organizational performance.

Sign in / Sign up

Export Citation Format

Share Document